XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Stockholders’ Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023   10,143      
Beginning balance at Dec. 31, 2023 $ 67,222 $ 1 $ 1,003,718 $ (473) $ (936,024)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 4,166   4,166    
Issuance of common stock and warrants for cash in private placement, net of issuance costs of $8,449 (in shares)   10,573      
Issuance of common stock and pre-funded warrants for cash in private placements, net of issuance costs of $8,449 119,361 $ 1 119,360    
Common stock issued upon exercise of stock options (in shares)   14      
Common stock issued upon exercise of stock options 139   139    
Common stock issued upon release of restricted stock units (in shares)   25      
Foreign currency translation adjustments (19)     (19)  
Unrealized loss on marketable securities, net (41)     (41)  
Net loss (27,147)       (27,147)
Ending balance (in shares) at Mar. 31, 2024   20,755      
Ending balance at Mar. 31, 2024 163,681 $ 2 1,127,383 (533) (963,171)
Beginning balance (in shares) at Dec. 31, 2024   20,848      
Beginning balance at Dec. 31, 2024 70,714 $ 2 1,138,070 (407) (1,066,951)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 2,778   2,778    
Common stock issued upon release of restricted stock units (in shares)   43      
Foreign currency translation adjustments 2     2  
Unrealized loss on marketable securities, net (53)     (53)  
Net loss (47,019)       (47,019)
Ending balance (in shares) at Mar. 31, 2025   20,891      
Ending balance at Mar. 31, 2025 $ 26,422 $ 2 $ 1,140,848 $ (458) $ (1,113,970)